Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy.

ABSTRACT: Oncogenesis is associated with intestinal dysbiosis, and stool shotgun metagenomic sequencing in individuals with this condition might constitute a non-invasive approach for the early diagnosis of several cancer types. The prognostic relevance of antibiotic intake and gut microbiota composition urged investigators to develop tools for the detection of intestinal dysbiosis to enable patient stratification and microbiota-centred clinical interventions. Moreover, since the advent of immune-checkpoint inhibitors (ICIs) in oncology, the identification of biomarkers for predicting their efficacy before starting treatment has been an unmet medical need. Many previous studies addressing this question, including a meta-analysis described herein, have led to the description of Gut OncoMicrobiome Sig

SUBMITTER: Thomas AM 

PROVIDER: S-EPMC11258874 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature